Yuanxia Gu
YOU?
Author Swipe
View article: <i>Eubacterium rectale</i>is a potential marker of altered gut microbiota in psoriasis and psoriatic arthritis
<i>Eubacterium rectale</i>is a potential marker of altered gut microbiota in psoriasis and psoriatic arthritis Open
Previous studies have profiled the gut microbiota among psoriatic patients compared to that among healthy individuals. However, a comprehensive understanding of the magnitude, direction, and detailed compositional and functional profiles r…
View article: A Propensity Score-Matched Study on the Changes of TB Status and TB-IGRA Values in Patients with Psoriasis with Latent TB Receiving Secukinumab
A Propensity Score-Matched Study on the Changes of TB Status and TB-IGRA Values in Patients with Psoriasis with Latent TB Receiving Secukinumab Open
View article: The Clinical Characteristics of Psoriatic Arthritis: A Cross-Sectional Study Based on the Psoriatic Arthritis Cohort of West China Hospital
The Clinical Characteristics of Psoriatic Arthritis: A Cross-Sectional Study Based on the Psoriatic Arthritis Cohort of West China Hospital Open
View article: The Characteristics of COVID‐19 Symptoms and Skin Manifestations among Nonhospitalized COVID‐19 Patients with Psoriasis during the Omicron Pandemic in China: A Single‐Center Survey‐Based Study
The Characteristics of COVID‐19 Symptoms and Skin Manifestations among Nonhospitalized COVID‐19 Patients with Psoriasis during the Omicron Pandemic in China: A Single‐Center Survey‐Based Study Open
Background . The global impact of coronavirus 2019 (COVID‐19) has raised concerns about the management of psoriasis patients, especially among those using biologics. Methods . We conducted a survey‐based research among Omicron‐infected (co…
View article: Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study Open
In real-world practice, SEC and ADA are effective and safe for moderate-to-severe plaque psoriasis treatment in Chinese patients. On the basis of drug prices during our study period without considering access to health insurance, ADA was m…
View article: The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in China
The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in China Open
View article: Development of a Predictive Model for Screening Patients with Psoriasis at Increased Risk of Psoriatic Arthritis
Development of a Predictive Model for Screening Patients with Psoriasis at Increased Risk of Psoriatic Arthritis Open
This study succeeded in developing a predictive model with a high degree of accuracy to predict the risk of PsA in patients with psoriasis.
View article: Effect of <i>NUDT15</i> polymorphisms on early hematological safety of low‐dose azathioprine in Chinese patients with pemphigus vulgaris: A prospective cohort study
Effect of <i>NUDT15</i> polymorphisms on early hematological safety of low‐dose azathioprine in Chinese patients with pemphigus vulgaris: A prospective cohort study Open
Azathioprine (AZA) is the preferred immunosuppressant for treating pemphigus vulgaris (PV), with discontinuation mainly attributed to hematological adverse events (AE). Reportedly, nucleoside diphosphate‐linked moiety X‐type motif 15 ( NUD…
View article: Correction to: Risk Factors for Progression from Subclinical to Clinical Phase of Psoriatic Arthritis: A Case–Control Study
Correction to: Risk Factors for Progression from Subclinical to Clinical Phase of Psoriatic Arthritis: A Case–Control Study Open
View article: Risk Factors for Progression from Subclinical to Clinical Phase of Psoriatic Arthritis: A Case–Control Study
Risk Factors for Progression from Subclinical to Clinical Phase of Psoriatic Arthritis: A Case–Control Study Open